Dalfampridine Prior Authorization Program: A Cohort Study

BACKGROUND: Dalfampridine (Ampyra) is indicated to improve walking in patients with multiple sclerosis (MS) and was found to be effective in 35%-43% of individuals with MS in clinical trials. Dalfampridine may increase seizure risk, particularly in patients with renal impairment. A U.S. managed care...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleason, Patrick P., Phillips, Jill, Fenrick, Beckie A., Delgado-Riley, Ana, Starner, Catherine I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437843/
https://www.ncbi.nlm.nih.gov/pubmed/23383704
http://dx.doi.org/10.18553/jmcp.2013.19.1.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437843/
https://www.ncbi.nlm.nih.gov/pubmed/23383704
http://dx.doi.org/10.18553/jmcp.2013.19.1.18

Ejemplares similares